Quantification of soluble-form signaling lymphocytic activation molecule family 7 (SLAMF7) and comprehensive gene expression analysis in serum samples among patients with relapsed/refractory multiple myeloma (RRMM): A multicenter prospective observational study (FBMTG RRMM18). - Quantification of SLAMF7 and comprehensive gene expression analysis in serum samples among patients with RRMM:(FBMTG RRMM18).

Fukuoka Blood and Marrow Transplant Group0 个研究点目标入组 100 人开始时间: 2019年7月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Treated with >=4 lines of prior chemo-radiotherapy. 2. Diagnosed as solitary plasmacytoma, plasma cell leukemia, or POEMS syndrome. 3. Positive results of either HIV-antibody, HBs-antigen, or HCV-antibody(except for HCV-PCR negativity). 4. Uncontrolled following diseases:liver dysfunction, renal dysfunction, cardiac dysfunction, respiratory dysfunction, diabetes, hypertension, infection. 5. Active advanced double-cancer (concurrently existed or <=5 years of disease free period, excluding Carcinoma in situ at uterine cervix, stomach, or colon). 6. Severe mental disorders such as schizophremia. 7. Pregnant women, possible of pregnancy, or during lactation. 8. Judged as inappropriate to participate in this study by doctor.

发起方

Fukuoka Blood and Marrow Transplant Group